Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Cell Reports. Medicine
|
July 14, 2022
CD8<sup>+</sup> T cells: An ineffective armor against prolonged COVID-19 in cancer patients
Oliver Van Oekelen, Samir Parekh
Advances in Experimental Medicine and Biology
|
March 1, 2022
Multi-Omics Profiling of the Tumor Microenvironment
Oliver Van Oekelen, Alessandro Laganà
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 14, 2024
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 27, 2018
Significance of prolonged QTc in acute exacerbations of COPD requiring hospitalization
Oliver Van Oekelen, Kristina Vermeersch, Stephanie Everaerts, et al.
Leukemia & Lymphoma
|
September 24, 2024
Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria
Sara Zhukovsky, Joshua White, Rajshekhar Chakraborty, et al.
British Journal of Haematology
|
February 26, 2026
Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed-methods study
Maria Mainou, Thomas Karagiannis, Eirini Pagkalidou, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2020
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
William E Pierceall, Michael D Amatangelo, Nizar J Bahlis, et al.
Journal of Hematology & Oncology
|
July 16, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Cell Reports. Medicine
|
May 22, 2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma
Michael Amatangelo, Erin Flynt, Nicholas Stong, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Cell Reports. Medicine
|
July 14, 2022
CD8<sup>+</sup> T cells: An ineffective armor against prolonged COVID-19 in cancer patients
Oliver Van Oekelen, Samir Parekh
Advances in Experimental Medicine and Biology
|
March 1, 2022
Multi-Omics Profiling of the Tumor Microenvironment
Oliver Van Oekelen, Alessandro Laganà
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 14, 2024
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 27, 2018
Significance of prolonged QTc in acute exacerbations of COPD requiring hospitalization
Oliver Van Oekelen, Kristina Vermeersch, Stephanie Everaerts, et al.
Leukemia & Lymphoma
|
September 24, 2024
Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria
Sara Zhukovsky, Joshua White, Rajshekhar Chakraborty, et al.
British Journal of Haematology
|
February 26, 2026
Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed-methods study
Maria Mainou, Thomas Karagiannis, Eirini Pagkalidou, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 25, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2020
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
William E Pierceall, Michael D Amatangelo, Nizar J Bahlis, et al.
Journal of Hematology & Oncology
|
July 16, 2020
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
Bo Wang, Oliver Van Oekelen, Tarek H Mouhieddine, et al.
Cell Reports. Medicine
|
May 22, 2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma
Michael Amatangelo, Erin Flynt, Nicholas Stong, et al.
Page
of 3